Wall Street Analysts Are Neutral on Top Healthcare Picks
Analysts fell to the sidelines weighing in on Cryo-Cell International (CCEL) and Gilead Sciences (GILD) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cryo-Cell International (CCEL)
Maxim Group analyst Allen Klee maintained a Hold rating on Cryo-Cell International yesterday. The company’s shares closed last Thursday at $3.66.
According to TipRanks.com, Klee has 0 stars on 0-5 stars ranking scale with an average return of
The the analyst consensus on Cryo-Cell International is currently a Hold rating.
See the top stocks recommended by analysts >>
Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences yesterday. The company’s shares closed last Thursday at $138.14.
According to TipRanks.com, Okunewitch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $159.47 average price target, a 15.0% upside from current levels. In a report issued on March 31, RBC Capital also maintained a Hold rating on the stock with a $118.00 price target.
Read More on CCEL:
